October 25, 2021 13:08 (IST)
Follow us:
facebook-white sharing button
twitter-white sharing button
instagram-white sharing button
youtube-white sharing button
Mann Ki Baat: PM Modi thanks 'lakhs of healthcare workers' for 1 billion Covid vaccination milestone | PM Modi, Amit Shah greet Indo-Tibetan Border Police on its Raising Day | Heavy firing in J&K's Poonch leaves three security personnel injured | Union Minister's son Ashish Mishra, accused in Lakhmipur Kheri violence, hospitalised | Lakhimpur Kheri violence: Three more arrested, say sources

Benefits of Pfizer Covid-19 vaccine for children surpass risks: US Drug Regulator

Washington/UNI/Sputnik: The benefits expected from the Pfizer Covid-19 vaccine shots for children between 5 and 11 years old outweigh the risks of side effects, the US Food and Drug Administration (FDA) said in a report.

Two doses of Pfizer-BioNTech vaccine are highly effective against COVID-19 hospitalizations for at least six months: Study

New York: Two doses of Pfizer-BioNTech (BNT162b2) are 90% effective against COVID-19 hospitalizations for all variants, including delta, for at least six months, confirms a new study from Kaiser Permanente and Pfizer published in The Lancet.

India won't buy 'expensive' Moderna, Pfizer Covid-19 shots as local production soars: Report

New Delhi/IBNS: India would not buy Covid-19 vaccines from foreign producers  Pfizer/BioNTech and Moderna as domestic production of the shots has increased manifold, Reuters reported citing sources.

Clinical trial results show Pfizer COVID-19 vaccine is safe for children aged between 5 to 11

New York: Pfizer Inc and BioNTech SE on Monday announced results from a Phase 2/3 trial showing a favorable safety profile and robust neutralizing antibody responses in children 5 to 11 years of age using a two-dose regimen of 10 µg administered 21 days apart, a smaller dose than the 30 µg dose used for people 12 and older.

Covid19: Centre reluctant on granting Moderna, Pfizer immunity from lawsuits, liability; excluded them from vaccination plan

New Delhi/IBNS: All US-based Covid-19 vaccine makers are insisting on protection from lawsuits and liability and India is reluctant to allow their entry on these conditions, delaying their availability in India, according to NK Arora, head of the government's vaccine panel.

Vaccine antibody levels start to wane at around 2-3 months: Study

London: Total antibody levels appear to start declining from as early as six weeks after complete vaccination and can reduce by more than 50% over 10 weeks, according to new data from UCL’s Virus Watch study.

Pfizer claims its Covid19 vaccine 'very effective' against Delta variant

New Delhi/IBNS: US pharma giant Pfizer, which is in the final stages of closing a coronavirus vaccine deal with the Indian government, has said its jab is very effective against the Delta variant of the virus, according to media reports.

CEO says Pfizer vaccine is effective against all existing COVID-19 variants

Washington/Sputnik: No COVID-19 variant has escaped the protection of Pfizer's vaccine, but the company continues to monitor and test it against emerging strains around the world, CEO Albert Bourla said on Thursday.

Pfizer to start testing COVID-19 vaccine in large group of children aged below 12

Pfizer on Tuesday said it will begin testing its COVID-19 vaccine on a larger group of children under the age of 12.

Gap between two Covid vaccine doses should be reduced to combat Delta variant: Lancet study

New Delhi/IBNS: Amid the spread of the Delta variant of coronavirus, which is dominant in India, the gap between the two doses should be reduced and boosters must be provided to those whose immunity may not be high enough, The Lancet journal said in a new study.

'Well established' foreign COVID-19 vaccines makers need no bridging clinical trials in India

New Delhi/IBNS: The Indian government has exempted "well established" foreign COVID-19 vaccines makers from any bridging clinical trials if it has been certified by the National Control Lab of the country where it is made, media reports said.

Pfizer's COVID vaccine approved for minors aged 12-15 in Japan

Moscow/Sputnik: The Japanese government approved Pfizer's COVID-19 vaccine for ages 12 to 15 on Monday, the media reported.

AstraZeneca-Oxford and Pfizer vaccines provide over 80 pc protection against Covid variant first found in India

London/IBNS: Two doses of AstraZeneca vaccine or Pfizer vaccine can give more than 80 per cent protection from the B1.617.2 variant of coronavirus first found in India, a new study conducted by the UK government has revealed, media reports said.

US regulator to authorize Pfizer-BioNTech vaccine for 12-15 year olds next week: Reports

Washinton/Sputnik: The US Food and Drug Administration (FDA) is preparing to approve the Pfizer-BioNTech COVID-19 vaccine for those aged 12 to 15, The New York Times reported, citing federal officials.

Pfizer in talks with India on vaccine approval; company pledges $70M in medicine donations

Pfizer is discussing with the Indian government expedited approval of its vaccine, company CEO Alber Bourla has said while announcing a donation of medicines worth $70 million to fight the resurgent pandemic.